After years of anticipation, the FDA’s Computer Software Assurance guidance is now official—and it materially reshapes how you validate production and quality system software.
On September 24, 2025, the FDA published the final approved guidance document “Computer Software Assurance for Production and Quality System Software.” This represents a major shift from rigid Computer System Validation (CSV) requirements toward a holistic, risk-based assurance model. The FDA recognizes the challenges with traditional CSV and is encouraging adoption of advanced manufacturing technologies by providing “a more iterative, agile approach” for software validation.
The CSA guidance also supports FDA’s broader initiative to modernize device regulation, aligning with the previously enacted least-burdensome approach—regulatory practices that achieve safety and effectiveness without unnecessary effort or documentation.
CSA applies to software used as part of:
CSA does not provide recommendations for:
This distinction helps you apply CSA appropriately—production and quality system software falls under this guidance, while product software requires separate validation approaches.
While the least-burdensome concept isn’t new to the FDA, streamlining validation practices while maintaining confidence in software is a big step forward.
Previously mandated CSV methods often led to extraneous validation efforts, where every system received the same level of scrutiny regardless of criticality. This added time, cost, and slowed adoption of modern technologies.
CSA guidance takes a different approach. Because the computer software assurance effort is risk-based, it follows a least-burdensome principle—validating only what’s necessary to address actual risk. This enables smarter resource allocation through:
The CSA approach supports efficiency in the rapidly evolving medical device landscape, allowing you to reduce time spent validating while remaining compliant. However, to gain CSA’s benefits, you must leverage your knowledge about specific processes and software features to appropriately assess risk and determine suitable assurance activities.
"The switch from CSV to CSA isn't simple—but thorough upfront work dramatically reduces ongoing documentation burden."
The guidance emphasizes “intended use” throughout—your assurance only works if it mirrors how you’ll actually use the software within your existing processes.
No amount of validation testing provides assurance unless it reflects how you’ll actually use the software within your existing processes. Before diving into risk assessment, work with your cross-functional team to answer these questions:
Define your intended use clearly, and you’ll scope assurance activities appropriately—reducing unnecessary validation while ensuring both practical functionality and robust compliance. Once you’ve comprehensively characterized the process and software to determine critical control points, it’s time to evaluate the risk.
Now that you’ve identified how the software will impact your manufacturing or quality processes, analyze the risks by systematically identifying reasonably foreseeable software failures, determining whether such failure poses a high process risk, and systematically selecting and performing assurance activities commensurate with the product or process risk.
Much like traditional risk assessment, you’ll consider the likelihood, impact, and detectability of failures—but there are a few distinctions.
The likelihood is framed as whether failures of specific software features, functions, or operations are “reasonably foreseeable” over the lifecycle of the affected production or quality process. FDA acknowledges a spectrum of process risks; for this guidance it presents risks in a binary manner (“high” vs. “not high”) to simplify decisions:
High Process Risk: Software failure to perform as intended may result in a quality problem that foreseeably compromises safety.
Not High Process Risk: Software failure to perform as intended would not result in a quality problem that foreseeably compromises safety, including situations that would result in a quality problem.
"Risk is contextual. Assessment must account not just for software features, but how they integrate into existing processes."
The main takeaway is that risk assessment must consider not only the software features, functions, and operations, but also how they’re incorporated into existing processes. Additional human awareness or review can significantly mitigate risk.
This risk-based mindset mirrors FDA’s push for holistic, least-burdensome approaches. Once intended use and risks are established, you’re ready to define corresponding assurance activities.
When it comes to compliance, the price of flexibility is effort. To fully enjoy the reduced need for testing and documentation, you must be prepared to justify your risk assessment and assurance activities without the comfort of feeling “covered” through completing the entire validation lifecycle for each system.
The CSA guidance advocates defining intended use, risk, and assurance activities based on individual software features, functions, and operations. Similar to how thorough root cause investigations drive effective Corrective and Preventive Actions (CAPAs), making the effort to comprehensively understand your processes, software, and associated risks will guide you to enacting appropriate assurance activities—with less documentation.
Follow this five-step flow that mirrors FDA’s Section V guidance:
The guidance outlines multiple testing approaches with examples of when each applies:
| Approach | Best For | Example |
|---|---|---|
| Unscripted testing | Lower-risk functions | Generating routine reports where reviewers can quickly verify outputs against expected results |
| Scripted testing | Higher-risk or complex functions | Automated batch release decisions that directly impact product quality |
| Exploratory testing | Functions suited to high-level objectives and pass/fail criteria | User workflows where step-by-step scripts aren’t necessary but objectives and acceptance criteria are clear |
| Scenario/error-guessing | Targeted evaluation of specific failure modes | Testing edge cases or unusual input combinations without formal test plans |
| Vendor-supplied evidence | When vendor controls are documented and trusted | Leveraging vendor audits, certifications (SOC 2, ISO 27001), secure SDLC evidence, cybersecurity documentation, SBOMs, release notes, and service agreements |
| Automated testing tools | Configurable or cloud-based systems | Continuous integration testing for SaaS platform updates with automatic regression checks |
The guidance encourages you to “consider the risk relative to the process,” detailing additional considerations for assurance activities. Additional controls throughout your quality system may mitigate the risk associated with software failure, including:
For example, a function that collects and records process data for review poses lower process risk than a function that determines product acceptability prior to human review. The capability to monitor and detect performance issues or system errors may reduce the risk associated with software failure, and you can consider this when deciding on assurance activities.
Manufacturers may rely on vendor audits and evaluations, certifications (such as SOC reports and ISO certifications), secure software development lifecycle (SDLC) evidence, cybersecurity documentation, Software Bills of Materials (SBOMs), release notes, and service agreements. You then determine your assurance activities proportionate to risk.
This doesn’t mean a vendor “validation package” alone equals compliance—you’re still responsible for understanding how the software fits your intended use and performing appropriate assurance activities. However, when vendors provide comprehensive documentation and evidence of their quality systems, you can leverage that work rather than recreating everything from scratch.
For purpose-built Good Practice (GxP) systems like Blue Mountain RAM, vendors provide GAMP 5-aligned materials and vendor evidence you can leverage as part of your own assurance—including functional specifications, traceability matrices, and testing documentation that accelerate your validation timeline.
When evaluating production and quality system software, ensure it meets foundational compliance requirements including 21 CFR Part 11 controls for electronic records and signatures. Learn what to look for in our practical buyer’s guide to selecting Part 11-compliant software.
| Traditional CSV | Risk-Based CSA |
|---|---|
| Validate entire system uniformly | Focus validation on high-risk functions |
| Manual test scripts for everything | Leverage vendor documentation where appropriate |
| Full revalidation on upgrades | Targeted regression testing based on risk |
| Months of validation effort | Weeks of validation effort with proper planning* |
| One-size-fits-all documentation | Documentation commensurate with risk |
*Customer-reported outcomes; actual timelines vary based on system complexity, organizational processes, and risk profile.
Like every other Good Practice (GxP) operation, the ultimate goal is generating appropriate objective evidence that clearly describes the assurance activities and results, as well as the underlying rationale.
Your CSA record should include:
If you’ve done the upfront work and the documentation contains sufficient details, you’ll have created a compliant CSA record that can serve as a baseline for future reference—both for issue resolution and planning for improvements.
CSA arrives alongside broader regulatory modernization. The Quality Management System Regulation (QMSR), which harmonizes Part 820 with ISO 13485, takes effect February 2, 2026. Together, these changes signal FDA’s shift toward international standards alignment, risk-based approaches, and recognition that modern software development practices (including cloud deployment and continuous updates) require flexible validation frameworks.
Organizations building quality systems now should consider how CSA fits within QMSR/ISO 13485 requirements for software validation, recognizing that risk-based assurance aligns naturally with quality management system principles.
Learn more about maintaining data integrity in modern GxP systems: Navigating Data Integrity Compliance
| In Scope (CSA Applies) | Out of Scope (Separate Requirements) |
|---|---|
| Computerized Maintenance Management Systems (CMMS) | Device software functions (SaMD/SiMD) |
| Quality Management Systems (QMS) | Software embedded in medical devices |
| Learning Management Systems (LMS) | Software that is itself a medical device |
| Manufacturing Execution Systems (MES) | Diagnostic or therapeutic software |
| Nonconformance Management Systems | Clinical decision support software |
| Business Intelligence/Analytics for Production | Patient monitoring software |
| Product Lifecycle Management (PLM) tools | |
| Electronic Batch Records |
Implementing CSA requires upfront evaluation and collaboration across IT, Quality, and Operations teams. But this finalized guidance empowers you to allocate testing, documentation, and oversight based on actual process risk—not blanket requirements that create busywork.
The organizations benefiting most from CSA are those starting with systems designed for risk-based validation. Purpose-built platforms like Blue Mountain RAM come with comprehensive GAMP 5-aligned materials and vendor evidence you can leverage as part of your own assurance, reducing the burden of creating documentation from scratch.
When selecting production and quality system software, ensure the platform meets foundational 21 CFR Part 11 requirements for electronic records, electronic signatures, and audit trails—these controls remain essential regardless of your CSA approach. Use our practical buyer’s guide to evaluate Part 11 compliance when vetting potential systems.
When you implement a purpose-built GMP platform, validation acceleration isn’t theoretical—it’s built into the system architecture. Blue Mountain RAM includes:
Organizations implementing purpose-built GMP systems have reported reducing validation timelines significantly compared to heavily customized generic platforms—though actual results depend on your system complexity, organizational processes, and risk profile. See how FUJIFILM Biosciences achieved validation efficiency.
Explore how purpose-built GMP systems help you maintain ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate—plus Complete, Consistent, Enduring, and Available) while implementing risk-based assurance aligned with FDA’s CSA guidance.
